Oral N-acetylglucosamine for Crohn's Disease
This study is testing an oral supplement called N-acetylglucosamine (GlcNAc) for people with Crohn's disease. Researchers want to see if GlcNAc can help improve symptoms and is safe to use. GlcNAc is a building block for important processes in your body that can affect gut health and inflammation. You could be eligible if you are 18 to 80 years old, have Crohn's disease affecting your small intestine or both small and large intestines, and are on stable Crohn's disease medication. The study will look at how many times your Crohn's disease gets worse (exacerbations) over several weeks. The current status of this study is unclear, and it plans to enroll 40 participants.
- Study design
- This is a placebo-controlled, cross-over study where participants will randomly receive either N-acetylglucosamine or a placebo (glucose) for 6 weeks. The study plans to enroll 40 participants.
- What's involved
- Participants will take N-acetylglucosamine or placebo three times daily for 6 weeks. You will also undergo genetic testing.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track the number of Crohn's disease exacerbations for up to 18 weeks after starting the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Oral N-acetylglucosamine in Crohn's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Joanna Melia, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and tolerability: Number of Crohn's disease exacerbationsWeeks 0-6, Weeks 6-9, Weeks 9-15, Weeks 15-18
Safety and tolerability will be defined as freedom from Crohn's disease (CD) disease exacerbation. Number of CD exacerbations will be one composite outcome with exacerbation of CD activity defined as the occurrence of ANY of the following during each treatment phase: i. Crohn's disease activity index (CDAI) score (patient reported measure) change of \>100 points, ii. initiation or change of CD therapy due to symptom worsening, iii. need for steroids related to CD disease activity, iv. CD-associated hospitalization, v. CD-associated surgery, vi. severe adverse events (CTCAE grade 3-5, attributed to CD disease activity, e.g. life-threatening perforation or sepsis)